CuraGen: Changes to Metabolic Disease Collaboration for the Development of BAY 76-7171
"Because of the changes we made to this product collaboration in December of last year, today's announcement has no direct impact on CuraGen with respect to near term value generation from our pipeline or on our resource allocation. We anticipate that the licensing effort by Bayer for this program will be positive and help support future development of BAY 76-7171, a small molecule compound being developed for potential use in the treatment of Type 2 diabetes," stated Dr. Frank M. Armstrong, President and Chief Executive Officer of CuraGen Corporation.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.